# PSMD4

Source: https://onco.cc/targets/psmd4/  
OnCo record `psmd4` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PSMD4 (26S proteasome non-ATPase regulatory subunit 4) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Colorectal cancer, Breast cancer and 2 more.

## Summary

Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair.

CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Talazoparib and Carfilzomib. Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.78, genetic association 0.12, clinical 0.99).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: proteasome 26S subunit ubiquitin receptor, non-ATPase 4; 26S proteasome non-ATPase regulatory subunit 4; S5A; AF-1; Rpn10
- Tags: cancer-genes-wave
- Symbol: PSMD4
- Class: other
- Biology: Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. PSMD4 acts as an ubiquitin receptor subunit through ubiquitin-interacting motifs and selects ubiquitin-conjugates for destruction. Displays a preferred selectivity for longer polyubiquitin chains. Locus 1q21.3 (HGNC).
- Where found: Multiple myeloma: Open Targets association 0.61 with plasma cell myeloma (MONDO_0009693); Colorectal cancer: CIViC evidence names this disease; Breast cancer: CIViC evidence names this disease; Non-Hodgkin lymphoma: Open Targets association 0.57 with non-Hodgkin lymphoma (MONDO_0018908); Mantle cell lymphoma: Open Targets association 0.54 with mantle cell lymphoma (MONDO_0018876)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99; CIViC holds 2 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:9561: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9561
- UniProt P55036: https://www.uniprot.org/uniprotkb/P55036/entry
- NCBI Gene 5710: https://www.ncbi.nlm.nih.gov/gene/5710
- Ensembl ENSG00000159352: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159352

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/psmd4.json